The additional funding reinforces Waiv’s momentum as the company advances clinical deployment and commercial expansion of its AI precision testing platform.
Waiv capitalizes on it’s industry-leading tech & AI stack to unlock morphological insights and future-proof the clinical diagnostic workflow.
Professor Fabrice André, alongside his colleagues at Gustave Roussy, participated in the research and development of RlapsRisk BC – a Waiv AI solution designed to help oncologists and pathologists access the risk of relapse for early breast cancer patients from pathology slide images.
The BRCA mutation has a fundamental role in the treatment of breast cancer. Experts from Gustave Roussy and the European Institute of Oncology dig into the clinical context that informs the development of BRCAura.
Understand how RlapsRisk BC delivers risk prognosis for early breast cancer from digitized H&E slides and clinical data — a next-generation mulitmodal-AI test.
The MSIntuit Suite features AI enabled testing for Microsatellite Instability (MSI) screening directly from H&E slides across several cancer types: Colorectal, Endometrial, and Gastric. Discover how it works.
Get to know BRCAura, an AI digital pathology based test designed to identify germline BRCA mutations from routine histology slides.
